Platelet count and bevacizumab response in high-grade glioma patients.

e13013 Background: Increased platelet count (PC) has been related to worse outcomes in solid tumors such as ovarian cancer. In high grade glioma (HGG) patients its role has not been elucidated. Although the exactly relationship between platelets and tumor cells is not clear, they may contribute to tumor growth and angiogenesis through growth factors and angiogenesis factors release such as VEGF. The aim of this work is to evaluate the associaton of PC with survival and response to bevacizumab in HGG patients. Methods: It is a retrospective review of eletronic medical charts from 45 patients with HGG treated with bevacizumab in second or later treatment lines. We evaluated the impact of high PC higher than median in overal survival (OS) and progression freee survival (PFS) by the log rank test and cox regression and overall response rate (ORR) assessed by MRI using chi-square test and logistic regression. Results: With a median follow-up time of 12.5 months the median OS (mOS) after bevacizumab was 14.6 mo...